Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.
DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.
DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.
Download Results (CSV)
|
Download Full Data Set (XLS)
| Condition |
Intervention
|
Intervention type
|
Intervention description |
Intervention setting
|
Objective
|
Target population
|
Cost effectiveness
(US$/DALY)
|
Cost effectiveness estimate
(US$)
|
Cost effectiveness range
(US$/DALY)
|
Number of DALYs averted
(hundreds)
|
Number of deaths averted
(hundreds)
|
Quality of cost-effectiveness analysis evidence
|
|
Malaria
|
Insecticidetreated bednets |
Population |
Impregnation of bednets with deltamethrin, one treatment of permethrin, or two treatments of permethrin, with the bednets either purchased or subsidized |
Home
|
control of environmental hazards
|
All ages, Adults, Infants or children, Women of childbearing age, Pregnant women, Adolescents and adults, Mothers and infants
|
11 (Sub-Saharan Africa) |
- |
5-17 (SubSaharan Africa) |
376.00 (SubSaharan Africa) |
1,429.60 (SubSaharan Africa) |
5 (SubSaharan Africa) |
|
Malaria
|
Intermittent preventive treatment in pregnancy with drug other than sulfadoxinepyrimethamine |
Personal |
Intermittent preventive treatment in areas with high and stable transmission of Plasmodium falciparum malaria; two curative doses of antimalarial treatment given with a possible change in first-line therapies from chloroquine to sulfadoxinepyrimethamine, |
Clinic
|
primary prevention
|
Adults, Women of childbearing age, Pregnant women, Adolescents and adults, Mothers and infants
|
7 (Sub-Saharan Africa) |
- |
2-11 (SubSaharan Africa) |
-- |
77,500.00 (SubSaharan Africa) |
5 (Sub-Saharan Africa) |
|
Malaria
|
Intermittent preventive treatment in pregnancy with sulfadoxinepyrimethamine |
Personal |
Intermittent preventive treatment in areas with high and stable transmission of Plasmodium falciparum malaria; two curative doses of sulfadoxine-pyrimethamine given during the second and third trimesters of pregnancy during prenatal care visits |
Clinic
|
primary prevention
|
Adults, Women of childbearing age, Pregnant women, Adolescents and adults, Mothers and infants
|
19 (Sub-Saharan Africa) |
- |
13-24 (Sub-Saharan Africa) |
208.00 (Sub-Saharan Africa) |
827.80 (Sub-Saharan Africa) |
5 (Sub-Saharan Africa) |
|
Malaria
|
Residual household spraying |
Population |
One or two doses of malathion, DDT, deltamethrin, or lambdacyhalothrin applied to household surfaces |
Home
|
control of environmental hazards
|
All ages, Adults, Infants or children, Women of childbearing age, Pregnant women, Adolescents and adults, Mothers and infants
|
17 (Sub-Saharan Africa) |
- |
9-24 (SubSaharan Africa) |
376.00 (SubSaharan Africa) |
1,429.60 (SubSaharan Africa) |
5 (SubSaharan Africa) |
Download Results (CSV)
|
Download Full Data Set (XLS)